Xiflam™ is an orally administered small molecule that targets the pathologically open Connexin43 (Cx43) hemichannel to treat diseases like diabetic retinopathy, diabetic nephropathy, and intermediate age-related macular degeneration by modulating the inflammasome pathway.

Xentry-Gap19 is a hemichannel blocking peptidomimetic linked to the cell-penetrating sequence Xentry, designed for rapid intervention in acute events such as stroke and myocardial infarction by inhibiting the release of ATP and activation of the inflammasome pathway.